Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature.
EORTC
Ovarian cancer
QLQ-C30
Quality of life
Systematic review
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
01
12
2021
accepted:
07
04
2022
pubmed:
24
4
2022
medline:
20
8
2022
entrez:
23
4
2022
Statut:
ppublish
Résumé
Chemotherapy is the cornerstone of adjuvant therapy in ovarian cancer. Its impact on the quality of life (QoL) has been addressed in several studies; however, several misperceptions concerning this affect patient counseling and physicians' ability to overcome patient fears. In the present systematic review, we sought to accumulate current evidence in the field in order to help establish robust information that will help physicians answer patients' questions. The present systematic review is based on the PRISMA guidelines. Studies that evaluated patient QoL pre-, during, and post-chemotherapy with the use of the QLQC-30 were selected for inclusion. Their methodological quality was assessed with the before-after studies tool that is proposed by the National Institute of Health (NIH). Ten studies that involved 5181 patients were included in the present systematic review. The risk of bias and methodological quality of included studies was of good and fair overall quality. Retrieved data suggest there is substantial evidence that points toward improved global QoL among ovarian cancer patients treated with taxanes-platinum combination therapy. Individual outcomes evaluated with the QLQ-C30 also provide positive results, although underreporting was noted. Despite the significant heterogeneity in outcome reporting, the findings of this study reveal the significant benefit of combined platinum taxane chemotherapy on the QoL of ovarian cancer patients and can be used for patients counseling in order to reduce refusals that arise from fear of adverse effects that may negatively affect QoL. Graphical abstract.
Identifiants
pubmed: 35459954
doi: 10.1007/s00520-022-07053-y
pii: 10.1007/s00520-022-07053-y
doi:
Substances chimiques
Bridged-Ring Compounds
0
Taxoids
0
taxane
1605-68-1
Platinum
49DFR088MY
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7147-7157Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, Roy JA, Piccart M, Eisenhauer E (2004) Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 22:4595–4603. https://doi.org/10.1200/jco.2004.08.080
doi: 10.1200/jco.2004.08.080
pubmed: 15466785
Bhat G, Karakasis K, Oza AM (2020) Measuring quality of life in ovarian cancer clinical trials – can we improve objectivity and cross trial comparisons? Cancers (Basel) 12. https://doi.org/10.3390/cancers12113296
Bhugwandass CS, Pijnenborg JM, Pijlman B, Ezendam NP (2016) Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based PROFILES registry. Curr Oncol 23:e556–e562. https://doi.org/10.3747/co.23.3243
doi: 10.3747/co.23.3243
pubmed: 28050144
pmcid: 5176381
Blagden SP, Cook AD, Poole C, Howells L, McNeish IA, Dean A, Kim JW, O’Donnell DM, Hook J, James EC, White IR, Perren T, Lord R, Dark G, Earl HM, Hall M, Kaplan R, Ledermann JA, Clamp AR (2020) Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncol 21:969–977. https://doi.org/10.1016/s1470-2045(20)30218-7
doi: 10.1016/s1470-2045(20)30218-7
pubmed: 32615110
pmcid: 7327508
Brotto L, Brundage M, Hoskins P, Vergote I, Cervantes A, Casado HA, Poveda A, Eisenhauer E, Tu D (2016) Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life. Support Care Cancer 24:1241–1249. https://doi.org/10.1007/s00520-015-2873-8
doi: 10.1007/s00520-015-2873-8
pubmed: 26304156
Chan YM, Ng TY, Ngan HY, Wong LC (2003) Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 88:9–16. https://doi.org/10.1006/gyno.2002.6849
doi: 10.1006/gyno.2002.6849
pubmed: 12504620
Chase DM, Wenzel L (2011) Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev Pharmacoecon Outcomes Res 11:421–431. https://doi.org/10.1586/erp.11.41
doi: 10.1586/erp.11.41
pubmed: 21831023
pmcid: 4920475
Citrin DL, Bloom DL, Grutsch JF, Mortensen SJ, Lis CG (2012) Beliefs and perceptions of women with newly diagnosed breast cancer who refused conventional treatment in favor of alternative therapies. Oncologist 17:607–612. https://doi.org/10.1634/theoncologist.2011-0468
doi: 10.1634/theoncologist.2011-0468
pubmed: 22531358
pmcid: 3360900
du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J (2010) Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 28:4162–4169. https://doi.org/10.1200/jco.2009.27.4696
doi: 10.1200/jco.2009.27.4696
pubmed: 20733132
Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G (2016) Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer 59:22–33. https://doi.org/10.1016/j.ejca.2016.01.017
doi: 10.1016/j.ejca.2016.01.017
pubmed: 26998845
Goldberg RJ (1983) Systematic understanding of cancer patients who refuse treatment. Psychother Psychosom 39:180–189. https://doi.org/10.1159/000287739
doi: 10.1159/000287739
pubmed: 6622631
Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A (2006) Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 24:579–586. https://doi.org/10.1200/jco.2005.02.4067
doi: 10.1200/jco.2005.02.4067
pubmed: 16446330
Guastalla JP 3rd, Diéras V (2003) The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer 89(Suppl 3):S16-22. https://doi.org/10.1038/sj.bjc.6601496
doi: 10.1038/sj.bjc.6601496
pubmed: 14661042
Haraldstad K, Wahl A, Andenæs R, Andersen JR, Andersen MH, Beisland E, Borge CR, Engebretsen E, Eisemann M, Halvorsrud L, Hanssen TA, Haugstvedt A, Haugland T, Johansen VA, Larsen MH, Løvereide L, Løyland B, Kvarme LG, Moons P, Norekvål TM, Ribu L, Rohde GE, Urstad KH, Helseth S (2019) A systematic review of quality of life research in medicine and health sciences. Qual Life Res 28:2641–2650. https://doi.org/10.1007/s11136-019-02214-9
doi: 10.1007/s11136-019-02214-9
pubmed: 31187410
pmcid: 6761255
Hess LM, Huang HQ, Hanlon AL, Robinson WR, Johnson R, Chambers SK, Mannel RS, Puls L, Davidson SA, Method M, Lele S, Havrilesky L, Nelson T, Alberts DS (2015) Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: an NRG oncology/gynecologic oncology group study. Gynecol Oncol 139:541–545. https://doi.org/10.1016/j.ygyno.2015.10.003
doi: 10.1016/j.ygyno.2015.10.003
pubmed: 26456812
pmcid: 4698796
Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, Katsumata N, Burger RA, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers RLM, Casado Herráez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K (2017) Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol 28:711–717. https://doi.org/10.1093/annonc/mdx011
doi: 10.1093/annonc/mdx011
pubmed: 28327917
Kim SI, Lee Y, Lim MC, Joo J, Park K, Lee DO, Park SY (2015) Quality of life and sexuality comparison between sexually active ovarian cancer survivors and healthy women. J Gynecol Oncol 26:148–154. https://doi.org/10.3802/jgo.2015.26.2.148
doi: 10.3802/jgo.2015.26.2.148
pubmed: 25686396
pmcid: 4397231
Lakusta CM, Atkinson MJ, Robinson JW, Nation J, Taenzer PA, Campo MG (2001) Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol 81:490–495. https://doi.org/10.1006/gyno.2001.6199
doi: 10.1006/gyno.2001.6199
pubmed: 11371144
Levin M, Mermelstein H, Rigberg C (1999) Factors associated with acceptance or rejection of recommendation for chemotherapy in a community cancer center. Cancer Nurs 22:246–250. https://doi.org/10.1097/00002820-199906000-00009
doi: 10.1097/00002820-199906000-00009
pubmed: 10376386
Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2007) Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol 25:2049–2056. https://doi.org/10.1200/jco.2006.09.1769
doi: 10.1200/jco.2006.09.1769
pubmed: 17513809
Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA, Hackl NA, Heading G (2011) Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol 22:2179–2190. https://doi.org/10.1093/annonc/mdq721
doi: 10.1093/annonc/mdq721
pubmed: 21339384
Luvero D, Milani A, Ledermann JA (2014) Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol 6:229–239. https://doi.org/10.1177/1758834014544121
doi: 10.1177/1758834014544121
pubmed: 25342990
pmcid: 4206613
Montazeri A, McEwen J, Gillis CR (1996) Quality of life in patients with ovarian cancer: current state of research. Support Care Cancer 4:169–179. https://doi.org/10.1007/bf01682336
doi: 10.1007/bf01682336
pubmed: 8739648
Plotti F, Scaletta G, Aloisi A, Luvero D, Capriglione S, Miranda A, Montera R, De Cicco Nardone C, Terranova C, Angioli R (2015) Quality of life in platinum-sensitive recurrent ovarian cancer: chemotherapy versus surgery plus chemotherapy. Ann Surg Oncol 22:2387–2394. https://doi.org/10.1245/s10434-014-4263-8
doi: 10.1245/s10434-014-4263-8
pubmed: 25582738
Roncolato FT, O’Connell RL, Joly F, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Salutari V, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Fehm T, Ledermann J, Roemer-Becuwe C, Stockler MR, King MT, Friedlander ML (2020) Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line (≥3) chemotherapy – the GCIG symptom benefit study (SBS). Gynecol Oncol 156:45–53. https://doi.org/10.1016/j.ygyno.2019.10.001
doi: 10.1016/j.ygyno.2019.10.001
pubmed: 31836184
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30. https://doi.org/10.3322/caac.21590
doi: 10.3322/caac.21590
pubmed: 31912902
Stavraka C, Ford A, Ghaem-Maghami S, Crook T, Agarwal R, Gabra H, Blagden S (2012) A study of symptoms described by ovarian cancer survivors. Gynecol Oncol 125:59–64. https://doi.org/10.1016/j.ygyno.2011.12.421
doi: 10.1016/j.ygyno.2011.12.421
pubmed: 22155797
Steppan I, Reimer D, Sevelda U, Ulmer H, Marth C, Zeimet AG (2009) Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin – an evaluation of the therapeutic index with special emphasis on cardiac toxicity. Chemotherapy 55:391–398. https://doi.org/10.1159/000262452
doi: 10.1159/000262452
pubmed: 19955744
Verhoef MJ, Rose MS, White M, Balneaves LG (2008) Declining conventional cancer treatment and using complementary and alternative medicine: a problem or a challenge? Curr Oncol 15(Suppl 2):s101-106. https://doi.org/10.3747/co.v15i0.281
doi: 10.3747/co.v15i0.281
pubmed: 18769571
pmcid: 2528553
von Gruenigen VE, Huang HQ, Gil KM, Gibbons HE, Monk BJ, Rose PG, Armstrong DK, Cella D, Wenzel L (2010) A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study. J Pain Symptom Manage 39:839–846. https://doi.org/10.1016/j.jpainsymman.2009.09.022
doi: 10.1016/j.jpainsymman.2009.09.022
Wallace SK, Lin JF, Cliby WA, Leiserowitz GS, Tergas AI, Bristow RE (2016) Refusal of recommended chemotherapy for ovarian cancer: risk factors and outcomes; a National Cancer Data Base Study. J Natl Compr Canc Netw 14:539–550. https://doi.org/10.6004/jnccn.2016.0062
doi: 10.6004/jnccn.2016.0062
pubmed: 27160232
Wallwiener M, Matthies L, Simoes E, Keilmann L, Hartkopf AD, Sokolov AN, Walter CB, Sickenberger N, Wallwiener S, Feisst M, Gass P, Fasching PA, Lux MP, Wallwiener D, Taran FA, Rom J, Schneeweiss A, Graf J, Brucker SY (2017) Reliability of an e-PRO Tool of EORTC QLQ-C30 for measurement of health-related quality of life in patients with breast cancer: prospective randomized trial. J Med Internet Res 19:e322. https://doi.org/10.2196/jmir.8210
doi: 10.2196/jmir.8210
pubmed: 28912116
pmcid: 5620457
Yang HC, Thornton LM, Shapiro CL, Andersen BL (2008) Surviving recurrence: psychological and quality-of-life recovery. Cancer 112:1178–1187. https://doi.org/10.1002/cncr.23272
doi: 10.1002/cncr.23272
pubmed: 18253948